Literature DB >> 33277307

Tumor-Infiltrating Natural Killer Cells.

Beatriz Cózar1, Marco Greppi1,2, Sabrina Carpentier1, Emilie Narni-Mancinelli3, Laura Chiossone1, Eric Vivier4,3,5.   

Abstract

Because of their potent antitumor activity and their proinflammatory role, natural killer (NK) cells are at the forefront of efforts to develop immuno-oncologic treatments. NK cells participate in immune responses to tumors by killing target cells and producing cytokines. However, in the immunosuppressive tumor microenvironment, NK cells become dysfunctional through exposure to inhibitory molecules produced by cancer cells, leading to tumor escape. We provide an overview of what is known about NK tumor infiltration and surveillance and about the mechanisms by which NK cells become dysfunctional. SIGNIFICANCE: The functions of tumor-infiltrating NK cells may be impaired. This review aims to describe the various mechanisms by which tumors alter NK-cell functions. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33277307      PMCID: PMC7611243          DOI: 10.1158/2159-8290.CD-20-0655

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  93 in total

1.  Antibody-dependent cell-mediated cytotoxicity due to a "null" lymphoid cell.

Authors:  A H Greenberg; L Hudson; L Shen; I M Roitt
Journal:  Nat New Biol       Date:  1973-03-28

2.  NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis.

Authors:  Ariella Glasner; Assi Levi; Jonatan Enk; Batya Isaacson; Sergey Viukov; Shari Orlanski; Alon Scope; Tzahi Neuman; Claes D Enk; Jacob H Hanna; Veronika Sexl; Stipan Jonjic; Barbara Seliger; Laurence Zitvogel; Ofer Mandelboim
Journal:  Immunity       Date:  2018-01-09       Impact factor: 31.745

3.  Accumulation of Tumor-Infiltrating CD49a+ NK Cells Correlates with Poor Prognosis for Human Hepatocellular Carcinoma.

Authors:  Haoyu Sun; Lianxin Liu; Qiang Huang; Huan Liu; Mei Huang; Jiabei Wang; Hao Wen; Renyong Lin; Kun Qu; Kun Li; Haiming Wei; Weihua Xiao; Rui Sun; Zhigang Tian; Cheng Sun
Journal:  Cancer Immunol Res       Date:  2019-07-16       Impact factor: 11.151

4.  Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells.

Authors:  Nicole Marquardt; Vivien Béziat; Sanna Nyström; Julia Hengst; Martin A Ivarsson; Eliisa Kekäläinen; Helene Johansson; Jenny Mjösberg; Magnus Westgren; Tim O Lankisch; Heiner Wedemeyer; Ewa C Ellis; Hans-Gustaf Ljunggren; Jakob Michaëlsson; Niklas K Björkström
Journal:  J Immunol       Date:  2015-02-11       Impact factor: 5.422

Review 5.  Natural killer cell-mediated immunosurveillance of human cancer.

Authors:  Karl-Johan Malmberg; Mattias Carlsten; Andreas Björklund; Ebba Sohlberg; Yenan T Bryceson; Hans-Gustaf Ljunggren
Journal:  Semin Immunol       Date:  2017-09-06       Impact factor: 11.130

6.  Increased sMICA and TGFβ1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells.

Authors:  Stephan Klöß; Nicole Chambron; Tanja Gardlowski; Lubomir Arseniev; Joachim Koch; Ruth Esser; Wolfgang Glienke; Oliver Seitz; Ulrike Köhl
Journal:  Oncoimmunology       Date:  2015-05-29       Impact factor: 8.110

7.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors:  François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

8.  NK cell phenotypic modulation in lung cancer environment.

Authors:  Shi Jin; Yi Deng; Jun-Wei Hao; Yang Li; Bin Liu; Yan Yu; Fu-Dong Shi; Qing-Hua Zhou
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

9.  Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.

Authors:  Qiong-Fang Zhang; Wen-Wei Yin; Yang Xia; Ya-Yang Yi; Qiu-Feng He; Xing Wang; Hong Ren; Da-Zhi Zhang
Journal:  Cell Mol Immunol       Date:  2016-06-20       Impact factor: 11.530

10.  The Atypical Chemokine Receptor Ackr2 Constrains NK Cell Migratory Activity and Promotes Metastasis.

Authors:  Christopher A H Hansell; Alasdair R Fraser; Alan J Hayes; Marieke Pingen; Claire L Burt; Kit Ming Lee; Laura Medina-Ruiz; Demi Brownlie; Megan K L Macleod; Paul Burgoyne; Gillian J Wilson; Robert J B Nibbs; Gerard J Graham
Journal:  J Immunol       Date:  2018-08-29       Impact factor: 5.422

View more
  55 in total

Review 1.  NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.

Authors:  Keywan Mortezaee; Jamal Majidpoor
Journal:  Med Oncol       Date:  2022-06-18       Impact factor: 3.064

2.  Role of NK Cells in Tumor Progression.

Authors:  Iñigo Terrén; Francisco Borrego
Journal:  Exp Suppl       Date:  2022

Review 3.  Roles of natural killer cells in immunity to cancer, and applications to immunotherapy.

Authors:  Natalie K Wolf; Djem U Kissiov; David H Raulet
Journal:  Nat Rev Immunol       Date:  2022-05-30       Impact factor: 108.555

Review 4.  Role of the ITAM-Bearing Receptors Expressed by Natural Killer Cells in Cancer.

Authors:  Hakim Medjouel Khlifi; Sophie Guia; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 5.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 6.  Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy.

Authors:  Lukman O Afolabi; Mariam O Afolabi; Musbahu M Sani; Wahab O Okunowo; Dehong Yan; Liang Chen; Yaou Zhang; Xiaochun Wan
Journal:  Clin Transl Immunology       Date:  2021-06-22

Review 7.  The Adverse Impact of Tumor Microenvironment on NK-Cell.

Authors:  Ziming Hu; Xiuxiu Xu; Haiming Wei
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

8.  Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy.

Authors:  Yuting Tang; Qian Xu; Liang Hu; Xiaomei Yan; Xiaomin Feng; Asumi Yokota; Weinan Wang; Di Zhan; Durga Krishnamurthy; David E Ochayon; Lijun Wen; Li Huo; Huimin Zeng; Yingwan Luo; L Frank Huang; Mark Wunderlich; Jiwang Zhang; Eric Vivier; Jianfeng Zhou; Stephen N Waggoner; Gang Huang
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 38.272

Review 9.  Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.

Authors:  Cai Zhang; Yuan Hu; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2021-07-15       Impact factor: 22.096

10.  Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers.

Authors:  Angela Tata; Garvin Dodard; Céline Fugère; Corinne Leget; Mélody Ors; Benjamin Rossi; Eric Vivier; Laurent Brossay
Journal:  Oncoimmunology       Date:  2021-06-15       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.